Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNYZ) Return on Sales (2016 - 2025)

Historic Return on Sales for Ligand Pharmaceuticals (LGNYZ) over the last 14 years, with Q3 2025 value amounting to 1.02%.

  • Ligand Pharmaceuticals' Return on Sales changed N/A to 1.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.19%, marking a year-over-year change of. This contributed to the annual value of 0.02% for FY2024, which is 100.0% down from last year.
  • Ligand Pharmaceuticals' Return on Sales amounted to 1.02% in Q3 2025.
  • Ligand Pharmaceuticals' Return on Sales' 5-year high stood at 1.02% during Q3 2025, with a 5-year trough of 0.94% in Q1 2025.
  • Moreover, its 5-year median value for Return on Sales was 0.07% (2021), whereas its average is 0.1%.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Return on Sales surged by 6300bps in 2021, and later crashed by -7100bps in 2024.
  • Over the past 5 years, Ligand Pharmaceuticals' Return on Sales (Quarter) stood at 0.04% in 2021, then tumbled by -49bps to 0.06% in 2022, then surged by 78bps to 0.01% in 2023, then crashed by -5627bps to 0.73% in 2024, then soared by 240bps to 1.02% in 2025.
  • Its Return on Sales was 1.02% in Q3 2025, compared to 0.1% in Q2 2025 and 0.94% in Q1 2025.